tbuckley/cabot-search huggingface dataset:
“Triple Therapy” or Triple Threat?: Balancing the Risks of Antithrombotic Therapy for Patients With Atrial Fibrillation and Coronary Stents⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Steven Francescone, Jonathan L. Halperin
Journal: Journal of the American College of Cardiology (2008)
Evaluation of a Transitional Care Program After Hospitalization for Heart Failure in an Integrated Health Care System
Authors: Aileen Baecker, Merry Meyers, Sandra Koyama, Maria Taitano, Heather Watson, Mary Machado, Huong Q. Nguyen
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Prompted by null findings from several care transition trials and practice changes for heart failure in recent years, leaders from a large integrated health care system aimed to reassess the outcomes of its 10-year multicomponent transitional care program for heart failure (HF-TCP). <h3>Objective</h3> To examine the association of the individual HF-TCP components and their bundle with the primary outcome of all-cause 30-day inpatient or observation stay readmissions. <h3>Design, Setting, and Participants</h3> This retrospective cohort study included patients enrolled in the HF-TCP during an inpatient encounter for heart failure at 13 Kaiser Permanente Southern California hospitals from January 1, 2013, to October 31, 2018, who were followed up from discharge until 30 days, readmission, or death. Data were analyzed from May 7, 2019, to May 1, 2020, with additional review from September 2 to October 1, 2020. <h3>Exposures</h3> Patients received 1 home health visit or telecare (telephone) visit from a registered nurse within 2 days of hospital discharge, a heart failure care manager call within 7 days, and a clinic visit with a physician or a nurse practitioner within 7 days. <h3>Main Outcomes and Measures</h3> Multivariable proportional hazards regression models were used to estimate the probability of 30-day readmission for those who received the individual or bundled HF-TCP components compared with those who did not. <h3>Results</h3> A total of 26 128 patients were included; 57.0% were male, and the mean (SD) age was 73 (13) years. The 30-day readmission rate was 18.1%. Both exposure to a home health visit within 2 days of discharge (hazard ratio [HR], 1.03; 95% CI, 0.96-1.10) and a 7-day heart failure case manager call (HR, 1.08; 95% CI, 0.99-1.18) compared with no visit or call were not associated with a lower rate of readmission. Completion of a 7-day clinic visit was associated with a lower readmission rate (HR, 0.88; 95% CI, 0.81-0.94) compared with no clinic visit. There were no synergistic effects of all 3 components compared with clinic visit alone (HR, 1.05; 95% CI, 0.87-1.28). <h3>Conclusions and Relevance</h3> This study found that HF-TCP as a whole was not associated with a reduction in 30-day readmission rates, although a follow-up clinic visit within 7 days of discharge may be helpful. These findings highlight the importance of continuous quality improvement and refinement of existing clinical programs.
Abstract 19854: Endothelial Microrna 335 is a Critical Determinant of Fatty Acid Uptake and Utilization
Authors: Takaomi Adachi, Devi Mehrotra, Omar El-Hely, Saejeong park, Yujung kang, Cheol hwangbo, Irinna Papangelli, Hyung Chun
Journal: Circulation (2017)

Endothelial determination of fatty acid uptake and transfer is beginning to emerge as a critical mechanism involved in diabetes and insulin resistance. MicroRNAs are emerging as key mediators of ce...
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype
Authors: Taofeek K. Owonikoko, Bhakti Dwivedi, Zhengjia Chen, Chao Zhang, Benjamin Barwick, Vinicius Ernani, Guojing Zhang, Melissa Gilbert-Ross, Jennifer Carlisle, Fadlo R. Khuri, Walter J. Curran, Andrey A. Ivanov, Haian Fu, Sagar Lonial, Suresh S. Ramalingam, Shi-Yong Sun, Edmund K. Waller, Gabriel L. Sica
Journal: Journal of Thoracic Oncology (2020)

IntroductionThe clinical and biological significance of the newly described SCLC subtypes, SCLC-A, SCLC-N, SCLC-Y, and SCLC-P, defined by the dominant expression of transcription factors ASCL1, NeuroD1, YAP1, and POU2F3, respectively, remain to be established.MethodsWe generated new RNA sequencing expression data from a discovery set of 59 archival tumor samples of neuroendocrine tumors and new protein expression data by immunohistochemistry in 99 SCLC cases. We validated the findings from this discovery set in two independent validation sets consisting of RNA sequencing data generated from 51 SCLC cell lines and 81 primary human SCLC samples.ResultsWe successfully classified 71.8% of SCLC and 18.5% of carcinoid cases in our discovery set into one of the four SCLC subtypes. Gene set enrichment analysis for differentially expressed genes between the SCLC survival outliers (top and bottom deciles) matched for clinically relevant prognostic factors revealed substantial up-regulation of interferon-γ response genes in long-term survivors. The SCLC-Y subtype was associated with high expression of interferon-γ response genes, highest weighted score on a validated 18-gene T-cell–inflamed gene expression profile score, and high expression of HLA and T-cell receptor genes. YAP1 protein expression was more prevalent and more intensely expressed in limited-stage versus extensive-stage SCLC (30.6% versus 8.5%; p = 0.0058) indicating good prognosis for the SCLC-Y subtype. We replicated the inflamed phenotype of SCLC-Y in the two independent validation data sets from the SCLC cell lines and tumor samples.ConclusionsSCLC subtyping using transcriptional signaling holds clinical relevance with the inflamed phenotype associated with the SCLC-Y subset.
“Madam, Methinks I See Him Living Yet” (John Milton, 1644): Predicting Full Recovery After Out-of-Hospital Cardiac Arrest⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Keith A. Comess, Kirk W. Beach
Journal: Journal of the American College of Cardiology (2012)
15849 Anal squamous cell carcinoma clinical outcome and receipt of chemoradiation with socioeconomic status
Authors: Albert Alhatem, Krishan S. Patel, Rutgers NJMS, Sushil Ahlawat, Michelle DallaPiazza, Katrice M. Karanfilian, Robert A. Schwartz, W. Clark Lambert
Journal: Journal of the American Academy of Dermatology (2020)
Antibacterial effects of platelet-rich fibrin produced by horizontal centrifugation
Authors: Mengge Feng, Yulan Wang, Peng Zhang, Qin Zhao, Shimin Yu, Kailun Shen, Richard J. Miron, Yufeng Zhang
Journal: International Journal of Oral Science (2020)

Abstract Platelet-rich fibrin (PRF) has been widely used owing to its ability to stimulate tissue regeneration. To date, few studies have described the antibacterial properties of PRF. Previously, PRF prepared by horizontal centrifugation (H-PRF) was shown to contain more immune cells than leukocyte- and platelet-rich fibrin (L-PRF). This study aimed to compare the antimicrobial effects of PRFs against Staphylococcus aureus and Escherichia coli in vitro and to determine whether the antibacterial effects correlated with the number of immune cells. Blood samples were obtained from eight healthy donors to prepare L-PRF and H-PRF. The sizes and weights of L-PRF and H-PRF were first evaluated, and their antibacterial effects against S. aureus and E. coli were then tested in vitro using the inhibition ring and plate-counting test methods. Flow-cytometric analysis of the cell components of L-PRF and H-PRF was also performed. No significant differences in size or weight were observed between the L-PRF and H-PRF groups. The H-PRF group contained more leukocytes than the L-PRF group. While both PRFs had notable antimicrobial activity against S. aureus and E. coli , H-PRF demonstrated a significantly better antibacterial effect than L-PRF. Furthermore, the antimicrobial ability of the PRF solid was less efficient than that of wet PRF. In conclusion, H-PRF exhibited better antibacterial activity than L-PRF, which might have been attributed to having more immune cells.
302MO Development of a flow cytometry-based whole-blood prognostic immune signature in metastatic cancer patients treated with immune checkpoint inhibitors
Authors: J-G. Zhou, A.J. Donaubauer, B. Frey, I. Becker, S. Rutzner, M. Eckstein, R. Sun, H. Ma, P. Schubert, C. Schweizer, R. Fietkau, E. Deutsch, U. Gaipl, M. Hecht
Journal: Annals of Oncology (2020)
Plasmodium falciparumマラリアの除去における大規模な薬剤投与の役割:コンセンサスモデリング研究【Powered by NICT】
Authors: Brady Oliver J, Slater Hannah C, Pemberton-Ross Peter, Wenger Edward, Maude Richard J, Ghani Azra C, Penny Melissa A, Gerardin Jaline, White Lisa J, Chitnis Nakul, Aguas Ricardo, Hay Simon I, Smith David L, Stuckey Erin M, Okiro Emelda A, Smith Thomas A, Okell Lucy C
Journal: The Lancet Global Health (2017)
58P Survival benefit of local treatments in breast cancer with lung metastasis: Results from a large retrospective study
Authors: Y. Chen, Q. Li, P. Zhang, P. Yuan, F. Ma, R. Cai, Y. Luo, Y. Fan, Q. Li, S. Chen, H. Mo, B. Lan, Y. Li, X. Guan, Z. Wang, S. Lin, J. Wang, B. Xu
Journal: Annals of Oncology (2020)
Abstract 16480: A Rare Case of Culture Negative Bartonella Endocarditis Resulting in Septic Coronary Embolism Presenting as ST Segment Elevation Myocardial Infarction
Authors: Jonathan Nattiv, Hussain Basrawala, Jennifer Tang, Anil Mehra, David Shavelle
Journal: Circulation (2019)

A 58-year-old homeless male with a history of hypertension and dyslipidemia presented with complaints of 4-weeks of worsening substernal chest pain, dyspnea, fevers and night sweats. Initial electr...
The Development of the von Willebrand Syndrome With the Use of Continuous Flow Left Ventricular Assist Devices: A Cause-and-Effect Relationship⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Leslie W. Miller
Journal: Journal of the American College of Cardiology (2010)
The Cancer-Associated ATM R3008H Mutation Reveals the Link between ATM Activation and Its Exchange
Authors: Maja Milanovic, Lisa Sprinzen, Demis Menolfi, Ji-Hoon Lee, Kenta Yamamoto, Yang Li, Brian J. Lee, Jun Xu, Verna M. Estes, Dong Wang, Peter J. Mckinnon, Tanya T. Paull, Shan Zha
Journal: Cancer Research (2020)

Abstract ATM kinase is a tumor suppressor and a master regulator of the DNA damage response. Most cancer-associated alterations to ATM are missense mutations at the PI3-kinase regulatory domain (PRD) or the kinase domain. Expression of kinase-dead (KD) ATM protein solely accelerates lymphomagenesis beyond ATM loss. To understand how PRD suppresses lymphomagenesis, we introduced the cancer-associated PRD mutation R3008H (R3016 in mouse) into mice. R3008H abrogated DNA damage- and oxidative stress-induced activation of ATM without consistently affecting ATM protein stability and recruitment. In contrast to the early embryonic lethality of AtmKD/KD mice, AtmR3016H (AtmR/R) mice were viable, immunodeficient, and displayed spontaneous craniofacial abnormalities and delayed lymphomagenesis compared with Atm−/− controls. Mechanistically, R3008H rescued the tardy exchange of ATM-KD at DNA damage foci, indicating that PRD coordinates ATM activation with its exchange at DNA-breaks. Taken together, our results reveal a unique tumorigenesis profile for PRD mutations that is distinct from null or KD mutations. Significant: This study functionally characterizes the most common ATM missense mutation R3008H in cancer and identifies a unique role of PI3-kinase regulatory domain in ATM activation.
Dissociable Motivational Deficits in Pre-manifest Huntington’s Disease
Authors: Kelly J. Atkins, Sophie C. Andrews, Julie C. Stout, Trevor T.-J. Chong
Journal: Cell Reports Medicine (2020)

Motivation is characterized by a willingness to overcome both cognitive and physical effort costs. Impairments in motivation are common in striatal disorders, such as Huntington's disease (HD), but whether these impairments are isolated to particular domains of behavior is controversial. We ask whether HD differentially affects the willingness of individuals to overcome cognitive versus physical effort. We tested 20 individuals with pre-manifest HD and compared their behavior to 20 controls. Across separate trials, participants made choices about how much cognitive or physical effort they were willing to invest for reward. Our key results were that individuals with pre-manifest HD were less willing than controls to invest cognitive effort but were no different in their overall preference for physical effort. These results cannot be explained by group differences in neuropsychological or psychiatric profiles. This dissociation of cognitive- and physical-effort-based decisions provides important evidence for separable, domain-specific mechanisms of motivation.
Mucormycosis the Emerging Global Threat; Overview and Treatment Outcome Among Pediatric Cancer Patients in Egypt
Authors: Yousef Madney, Reham Khedr, Hadir Al-Mahellawy, Naglaa Adel, Hala Taha, Iman Zaki, Ayda Youssef, Gehad Taha, Omaima Hassanain, Hanafy Hafez
Journal: Blood (2017)
213P Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Authors: G.T. Quah, D. Espinoza, M. Crumbaker, B. Balakrishnar, M. Arasaratnam, S. Bariol, A. Brooks, H. Lau, M. Patel, H. Gurney
Journal: Annals of Oncology (2020)
Vitamin D Treatment during Pregnancy and Maternal and Neonatal Cord Blood Metal Concentrations at Delivery: Results of a Randomized Controlled Trial in Bangladesh
Authors: Anne Marie Z. Jukic, Anna Zuchniak, Huma Qamar, Tahmeed Ahmed, Abdullah Al Mahmud, Daniel E. Roth
Journal: Environmental Health Perspectives (2020)

Background: Vitamin D improves absorption of calcium; however, in animal studies vitamin D also increases the absorption of toxic metals, such as lead and cadmium. Objectives: We examined maternal and neonatal cord blood levels of lead, cadmium, manganese, and mercury after supplementation with vitamin D during pregnancy. Methods: The Maternal Vitamin D for Infant Growth trial was a randomized, placebo-controlled, multi-arm study of maternal vitamin D supplementation during pregnancy in Dhaka, Bangladesh (NCT01924013). Women were randomized during their second trimester to blinded weekly doses of placebo or 4,200, 16,800, or 28,000 IU of vitamin D3 throughout pregnancy. Each group had 118–239 maternal blood specimens and 100–201 cord blood samples analyzed. Metals were measured using inductively coupled plasma mass spectrometry. Unadjusted estimates from linear regression models were expressed as percentage differences. Cord blood cadmium was analyzed as detectable or undetectable with log-binomial regression. Results: Maternal cadmium, mercury, and manganese levels were nearly identical across groups. Maternal lead levels were 6.3%, 7.4%, and 6.0% higher in the treatment groups (4,200, 16,800, and 28,000 IU, respectively) vs. placebo; however, 95% confidence intervals (CIs) showed that differences from 4.1% lower to 20% higher were compatible with the data. In treatment groups (4,200, 16,800, 28,000 IU) vs. placebo, neonatal cord blood lead levels were 8.5% (95% CI: −3.5, 22), 16% (95% CI: 3.3, 30), and 11% (95% CI: 0.4, 23) higher and had higher risk of detectable cadmium, relative risk (RR)=2.2 (95% CI: 1.3, 3.7), RR=1.4 (95% CI: 0.8, 2.5), RR=1.7 (95% CI: 1.0, 2.9). Discussion: Vitamin D supplementation from the second trimester of pregnancy did not influence maternal cadmium, mercury, or manganese levels at delivery. Vitamin D was associated with nonsignificant increases in maternal lead and with significant increases in cord blood lead and cadmium. These associations were not dose dependent. Given that there are no safe levels of metals in infants, the observed increases in cord blood lead and cadmium require further exploration. https://doi.org/10.1289/EHP7265
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
Authors: Xenofon Baraliakos, Laure Gossec, Effie Pournara, Slawomir Jeka, Antonio Mera-Varela, Salvatore D'Angelo, Barbara Schulz, Michael Rissler, Kriti Nagar, Chiara Perella, Laura C Coates
Journal: Annals of the Rheumatic Diseases (2020)

MAXIMISE (Managing AXIal Manifestations in psorIatic arthritis with SEcukinumab) trial was designed to evaluate the efficacy of secukinumab in the management of axial manifestations of psoriatic arthritis (PsA).This phase 3b, double-blind, placebo-controlled, multi-centre 52-week trial included patients (≥18 years) diagnosed with PsA and classified by ClASsification criteria for Psoriatic Arthritis (CASPAR) criteria, with spinal pain Visual Analogue Score ≥40/100 and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥4 despite use of at least two non-steroidal anti-inflammatory drugs (NSAIDs). Patients were randomised (1:1:1) to secukinumab 300 mg, secukinumab 150 mg or placebo weekly for 4 weeks and every 4 weeks thereafter. At week 12, placebo patients were re-randomised to secukinumab 300/150 mg. Primary endpoint was ASAS20 (Assessment of SpondyloArthritis international Society) response with secukinumab 300 mg at week 12.Patients were randomly assigned; 167 to secukinumab 300 mg, 165 to secukinumab 150 mg and 166 to placebo. Secukinumab 300 mg and 150 mg significantly improved ASAS20 response versus placebo at week 12 (63% and 66% vs 31% placebo). The OR (95% CI) comparing secukinumab 300 mg and 150 mg versus placebo, using a logistic regression model after multiple imputation, was 3.8 (2.4 and 6.1) and 4.4 (2.7 and 7.0; p<0.0001).Secukinumab 300 mg and 150 mg provided significant improvement in signs and symptoms of axial disease compared with placebo in patients with PsA and axial manifestations with inadequate response to NSAIDs.NCT02721966.
Biology and dynamics of B cells in the context of IgE‐mediated food allergy
Authors: Pattraporn Satitsuksanoa, Monique Daanje, Mübeccel Akdis, Scott D. Boyd, Willem van de Veen
Journal: Allergy (2020)

Abstract An increasing number of people suffer from IgE‐mediated food allergies. The immunological mechanisms that cause IgE‐mediated food allergy have been extensively studied. B cells play a key role in the development of IgE‐mediated food allergies through the production of allergen‐specific antibodies. While this particular function of B cells has been known for many years, we still do not fully understand the mechanisms that regulate the induction and maintenance of allergen‐specific IgE production. It is still not fully understood where in the body IgE class switch recombination of food allergen‐specific B cells occurs, and what processes are involved in the immunological memory of allergen‐specific IgE responses. B cells can also contribute to the regulation of allergen‐specific immune responses through other mechanisms such as antigen presentation and cytokine production. Recent technological advances have enabled highly detailed analysis of small subsets of B cells down to the single‐cell level. In this review, we provide an overview of the current knowledge on the biology of B cells in relation to IgE‐mediated food allergies.
Psychological interventions to prevent the onset of depressive disorders: A meta-analysis of randomized controlled trials
Authors: Pim Cuijpers, Blanca S. Pineda, Soledad Quero, Eirini Karyotaki, Sascha Y. Struijs, Caroline A. Figueroa, Jazmin A. Llamas, Toshi A. Furukawa, Ricardo F. Muñoz
Journal: Clinical Psychology Review (2020)

Depressive disorders are common and have a considerable impact on patients and societies. Several treatments are available, but their effects are modest and reduce the burden only to a limited extent. Preventing the onset of depressive disorders may be one option to further reduce the global disease burden. We conducted a meta-analysis of randomized controlled trials in participants without a diagnosis of depression at baseline, who were assigned to a preventive psychological intervention, or a care-as-usual, or comparable control group and in which incident cases of depression at follow-up were ascertained with a diagnostic interview. Our systematic searches resulted in 50 trials (14,665 participants) with relatively high quality, in high risk groups of all ages. The psychological interventions were mostly based on cognitive behavioral interventions. One year after the preventive interventions, the relative risk of developing a depressive disorder was RR = 0.81 (95% CI: 0.72–0.91), indicating that those who had received the intervention had 19% less chance to develop a depressive disorder. Given the average control event rate of 30%, twenty-one people had to participate in the intervention to prevent one depressive disorder compared to people in the control conditions. Prevention is a promising approach to reduce the global disease burden of depression in addition to treatments.
DICOM Integration Libraries for Medical Image Interoperability: A Technical Review
Authors: Manisha Mantri, Shruti Taran, Gaur Sunder
Journal: IEEE Reviews in Biomedical Engineering (2020)

Medical images support diagnostic care and research in medicine. The acquisition and availability of medical images in digital form can facilitate quick diagnosis, ease of access, continuity of care, analysis and contribute to modern medical research. Digital Imaging and Communications in Medicine (DICOM) is a universal standard that promises standardized representation and exchange of medical images and related information from various radiological and waveform sources. DICOM software development kits or tools or libraries make it easier to implement DICOM standard in healthcare applications. There are several such API libraries available from different providers that promise DICOM integration. In this paper, we explore available DICOM API libraries and conduct a comparative study between a set of selected libraries on the four major criteria (DICOM features, technical aspects, the robustness of the library, and the level of user support available). The aim is to provide a complete picture of options available that can help in finding a best-fit open-source DICOM standard integration API library for developing standardized and interoperable healthcare applications.